M&As this week: RXi Pharmaceuticals, TFS International, Danaher Corporation

13th October 2016 (Last Updated October 13th, 2016 18:30)

RXi Pharmaceuticals plans to expand its product pipeline and enter the immuno-oncology market by acquiring all the outstanding shares of cancer immunotherapies developer MirImmune.

RXi Pharmaceuticals plans to expand its product pipeline and enter the immuno-oncology market by acquiring all the outstanding shares of cancer immunotherapies developer MirImmune.

Pursuant to the agreement, RXi Pharma will develop new immuno-oncology products by using its proprietary sd-rx RNA platform.

"TFS International plans to expand its presence in the Europe and North America markets through the acquisition of SCIderm."

TFS International plans to expand its presence in the Europe and North America markets through the acquisition of SCIderm.

The acquisition enables TFS International to offer customer services to 350 investigational sites and develop new treatments in the therapeutic areas of allergology, dermatology and aesthetics.

Medical products and service provider Danaher Corporation has entered a definitive agreement to acquire Phenomenex, a high-value consumables manufacturer and distributor.

The acquisition enables Phenomenex to strengthen its research and development (R&D) and expand its product portfolio, while it allows Danaher Corporation to further develop its Danaher Business System (DBS) tools.